JP2008516958A - 変形性関節症の治療及びアルゾキシフェンの投与計画 - Google Patents
変形性関節症の治療及びアルゾキシフェンの投与計画 Download PDFInfo
- Publication number
- JP2008516958A JP2008516958A JP2007536834A JP2007536834A JP2008516958A JP 2008516958 A JP2008516958 A JP 2008516958A JP 2007536834 A JP2007536834 A JP 2007536834A JP 2007536834 A JP2007536834 A JP 2007536834A JP 2008516958 A JP2008516958 A JP 2008516958A
- Authority
- JP
- Japan
- Prior art keywords
- arzoxifene
- week
- dosage unit
- once
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 118
- MCGDSOGUHLTADD-UHFFFAOYSA-N arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 title claims description 102
- 229950005529 arzoxifene Drugs 0.000 title claims description 100
- 238000011282 treatment Methods 0.000 title claims description 48
- 238000000034 method Methods 0.000 claims abstract description 65
- 241000124008 Mammalia Species 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 239000012453 solvate Substances 0.000 claims abstract description 13
- 208000024891 symptom Diseases 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 11
- 230000037182 bone density Effects 0.000 claims description 8
- 208000001132 Osteoporosis Diseases 0.000 claims description 7
- 208000006386 Bone Resorption Diseases 0.000 claims description 6
- 230000024279 bone resorption Effects 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 210000000845 cartilage Anatomy 0.000 description 35
- 241000219061 Rheum Species 0.000 description 33
- 206010003246 arthritis Diseases 0.000 description 23
- 239000000090 biomarker Substances 0.000 description 23
- 230000003442 weekly effect Effects 0.000 description 21
- 210000003127 knee Anatomy 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 15
- 238000002595 magnetic resonance imaging Methods 0.000 description 15
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 13
- 210000000988 bone and bone Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 229920002674 hyaluronan Polymers 0.000 description 13
- 229960003160 hyaluronic acid Drugs 0.000 description 13
- 102000055007 Cartilage Oligomeric Matrix Human genes 0.000 description 10
- 101710176668 Cartilage oligomeric matrix protein Proteins 0.000 description 10
- 238000005259 measurement Methods 0.000 description 9
- 238000002601 radiography Methods 0.000 description 9
- 241000700198 Cavia Species 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 210000001503 joint Anatomy 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 230000007423 decrease Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000000689 upper leg Anatomy 0.000 description 7
- 210000001188 articular cartilage Anatomy 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000000629 knee joint Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 206010061818 Disease progression Diseases 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000005750 disease progression Effects 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 230000009245 menopause Effects 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 210000001179 synovial fluid Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 230000008468 bone growth Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000007012 clinical effect Effects 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 210000001624 hip Anatomy 0.000 description 4
- 238000010191 image analysis Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 102000000503 Collagen Type II Human genes 0.000 description 3
- 108010041390 Collagen Type II Proteins 0.000 description 3
- 206010027304 Menopausal symptoms Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000011597 hartley guinea pig Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 210000001258 synovial membrane Anatomy 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 description 2
- DPXVERXWXRQEDB-UHFFFAOYSA-N 2-(4-methoxyphenyl)-4-[4-(2-piperidin-1-ylethoxy)phenoxy]-1-benzothiophen-6-ol Chemical compound COC1=CC=C(C=C1)C2=CC3=C(C=C(C=C3S2)O)OC4=CC=C(C=C4)OCCN5CCCCC5 DPXVERXWXRQEDB-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000029725 Metabolic bone disease Diseases 0.000 description 2
- 206010049088 Osteopenia Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000469816 Varus Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960002849 glucosamine sulfate Drugs 0.000 description 2
- 238000011554 guinea pig model Methods 0.000 description 2
- 210000004394 hip joint Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000024765 knee pain Diseases 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 230000030991 negative regulation of bone resorption Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000000101 novel biomarker Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 201000004595 synovitis Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010051763 Bone marrow oedema Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 102100038196 Chitinase-3-like protein 1 Human genes 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 101150014058 MMP1 gene Proteins 0.000 description 1
- 238000012307 MRI technique Methods 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 108010076503 Matrix Metalloproteinase 13 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003433 aortic smooth muscle cell Anatomy 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000011882 arthroplasty Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 108700004333 collagenase 1 Proteins 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000002436 femur neck Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000011540 hip replacement Methods 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 102000054350 human CHI3L1 Human genes 0.000 description 1
- 210000003035 hyaline cartilage Anatomy 0.000 description 1
- 201000010930 hyperostosis Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000013150 knee replacement Methods 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000012148 non-surgical treatment Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000001171 synovial bursa Anatomy 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62020204P | 2004-10-19 | 2004-10-19 | |
| PCT/US2005/036662 WO2006044451A1 (en) | 2004-10-19 | 2005-10-13 | Treatment of osteoarthritis and dosing regimen for arzoxifene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008516958A true JP2008516958A (ja) | 2008-05-22 |
| JP2008516958A5 JP2008516958A5 (enExample) | 2008-11-20 |
Family
ID=35615492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007536834A Withdrawn JP2008516958A (ja) | 2004-10-19 | 2005-10-13 | 変形性関節症の治療及びアルゾキシフェンの投与計画 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20070249677A1 (enExample) |
| EP (1) | EP1807079A1 (enExample) |
| JP (1) | JP2008516958A (enExample) |
| CA (1) | CA2584747A1 (enExample) |
| WO (1) | WO2006044451A1 (enExample) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5510357A (en) * | 1995-02-28 | 1996-04-23 | Eli Lilly And Company | Benzothiophene compounds as anti-estrogenic agents |
| WO2005123130A2 (en) * | 2004-06-17 | 2005-12-29 | Osteologix A/S | Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor |
-
2005
- 2005-10-13 WO PCT/US2005/036662 patent/WO2006044451A1/en not_active Ceased
- 2005-10-13 EP EP05808600A patent/EP1807079A1/en not_active Withdrawn
- 2005-10-13 US US11/575,429 patent/US20070249677A1/en not_active Abandoned
- 2005-10-13 CA CA002584747A patent/CA2584747A1/en not_active Abandoned
- 2005-10-13 JP JP2007536834A patent/JP2008516958A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006044451A1 (en) | 2006-04-27 |
| EP1807079A1 (en) | 2007-07-18 |
| CA2584747A1 (en) | 2006-04-27 |
| US20070249677A1 (en) | 2007-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10882860B2 (en) | Treatment of osteoarthritis | |
| Sharma et al. | Knee adduction moment, serum hyaluronan level, and disease severity in medial tibiofemoral osteoarthritis | |
| Pallan et al. | Diagnosis and management of primary hyperparathyroidism | |
| Teasell et al. | A systematic review of the therapeutic interventions for heterotopic ossification after spinal cord injury | |
| Bruyere et al. | Radiologic features poorly predict clinical outcomes in knee osteoarthritis | |
| US20210186990A1 (en) | Methods and compositions for treating various disorders | |
| Mapp et al. | Effects of a metalloproteinase inhibitor on osteochondral angiogenesis, chondropathy and pain behavior in a rat model of osteoarthritis | |
| Hooper et al. | Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial | |
| JP2023058550A (ja) | 変形性関節症の治療に使用するための製剤 | |
| Garland et al. | Fracture threshold and risk for osteoporosis and pathologic fractures in individuals with spinal cord injury | |
| Hammoud et al. | Does the severity of obesity influence bone mineral density values in premenopausal women? | |
| Cooper et al. | Bone abnormalities and severe arthritis in pachydermoperiostosis. | |
| Siris | Alendronate in the treatment of osteoporosis: a review of the clinical trials | |
| Diamond et al. | Guidelines for the management of postmenopausal osteoporosis for GPs | |
| Norimatsu et al. | Effects of low-intensity exercise on spontaneously developed knee osteoarthritis in male senescence-accelerated mouse prone 8 | |
| Ruan et al. | Can metformin relieve tibiofemoral cartilage volume loss and knee symptoms in overweight knee osteoarthritis patients? Study protocol for a randomized, double-blind, and placebo-controlled trial | |
| Iwamoto et al. | Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis | |
| Takahashi et al. | Obesity is a risk factor for osteoarthritis progression and spontaneous osteoporosis is a risk for the development of spontaneous osteonecrosis in patients with medial meniscus posterior root tear | |
| Vasiliadis et al. | Single-dose therapy of zoledronic acid for the treatment of primary bone marrow edema syndrome | |
| JP2008516958A (ja) | 変形性関節症の治療及びアルゾキシフェンの投与計画 | |
| Yoshizawa et al. | Zoledronic acid for osteoporosis after distal radius fracture surgery: Prospective longitudinal study | |
| JP2002518326A (ja) | 筋骨格脆性治療のための（選択的）エストロゲンレセプターモジュレーター（ｓｅｒｍ）及び成長ホルモン分泌促進剤（ｇｈｓ）の治療用組合せ | |
| Amorim et al. | Injection of kaolin/carrageenan in the rat knee joint induces progressive experimental knee osteoarthritis | |
| Singh et al. | A Review article on Diclofenac Sodium Topical gel on Osteoarthritis | |
| Devogelaer et al. | Osteogenesis imperfecta: current treatment options and future prospects |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081001 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081001 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20100406 |